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Background: The electronic self report assessment - cancer (ESRA-C), has been shown to reduce symptom distress
during cancer therapy The purpose of this analysis was to evaluate aspects of how the ESRA-C intervention may
have resulted in lower symptom distress (SD).
Methods: Patients at two cancer centers were randomized to ESRA-C assessment only (control) or the Web-based
ESRA-C intervention delivered to patients’ homes or to a tablet in clinic. The intervention allowed patients to
self-monitor symptom and quality of life (SxQOL) between visits, receive self-care education and coaching to report
SxQOL to clinicians. Summaries of assessments were delivered to clinicians in both groups. Audio-recordings of
clinic visits made 6 weeks after treatment initiation were coded for discussions of 26 SxQOL issues, focusing on
patients’/caregivers’ coached verbal reports of SxQOL severity, pattern, alleviating/aggravating factors and requests
for help. Among issues identified as problematic, two measures were defined for each patient: the percent SxQOL
reported that included a coached statement, and an index of verbalized coached statements per SxQOL. The
Wilcoxon rank test was used to compare measures between groups. Clinician responses to problematic SxQOL were
compared. A mediation analysis was conducted, exploring the effect of verbal reports on SD outcomes.
Results: 517 (256 intervention) clinic visits were audio-recorded. General discussion of problematic SxQOL was similar
in both groups. Control group patients reported a median 75% of problematic SxQOL using any specific coached
statement compared to a median 85% in the intervention group (p = .0009). The median report index of coached
statements was 0.25 for the control group and 0.31 for the intervention group (p = 0.008). Fatigue, pain and physical
function issues were reported significantly more often in the intervention group (all p < .05). Clinicians' verbalized
responses did not differ between groups. Patients' verbal reports did not mediate final SD outcomes (p = .41).
Conclusions: Adding electronically-delivered, self-care instructions and communication coaching to ESRA-C promoted
specific patient descriptions of problematic SxQOL issues compared with ESRA-C assessment alone. However, clinician
verbal responses were no different and subsequent symptom distress group differences were not mediated by the
patients' reports.
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Figure 1 Health outcomes model adapted to these analyses.
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Patient-clinician communication has been evaluated and
found lacking with regard to clinician assessment of pa-
tient experiences, notably symptoms and quality-of-life is-
sues (SxQOL) [1-3], and verbal patient reports of SxQOL
[4]. Barriers to communication in the oncology setting
have been identified and include 1) clinician-oriented
verbal behaviors: use of close-ended (versus open-ended)
queries and interruptions of patient symptom descriptions
[5,6], changing the subject after a patient verbally reports
an SxQOL; [7] 2) clinician beliefs that quality of life is-
sues are other clinicians' responsibility [8], 3) patient-
oriented issues: reluctance to verbalize problems [9], re-
call of SxQOL experiences in between visits [10], and 4)
time limitations during the visit [11]. When clinicians are
unaware of SxQOL, particularly treatment-related toxic-
ities, there is danger of higher morbidity and even mortality
related to unintentional over-dosing [12,13]. Interventions
to improve patient-clinician communication have been
tested with modest, but positive, results [9,14-16].
In the first electronic self report assessment for cancer
(ESRA-C) randomized clinical trial [17], we demonstrated
the feasibility, acceptability and efficacy of computerized
SxQOL screening at a large comprehensive cancer center
in Seattle, significantly increasing the frequency of pa-
tient/clinician communication about problematic issues as
measured in audio-recorded clinic visits. Yet, we found
that even when clinicians received summaries of patient-
reported SxQOL, the most frequently addressed issues
were those either regulated by certification bodies (e.g.,
pain) or likely to be affected by supportive care medica-
tions previously ordered by the clinician (e.g., nausea
with anti-emetics). High distress SxQOL reported by
patients on the ESRA-C measure were often left unad-
dressed by clinicians [6,7]. A second randomized trial
(ESRA-C II) in which the clinician summary interven-
tion was delivered for all participant clinic visits, tested
a new intervention that offered SxQOL tracking, tai-
lored education and communication coaching directly
to patients recruited from two comprehensive cancer
centers. The results from ESRA-C II indicated signifi-
cantly lower symptom distress over the course of ther-
apy with the intervention [18]. Because ESRA-C was a
multi-component intervention, we wanted to understand
more about the impact of the communication coaching
on the verbal behaviors of patients during the face-to-face
visit. The purpose of this analysis was to compare verbal
reports of SxQOL between the study groups with regard
to: 1) reported severity, pattern, alleviating/aggravating
factors and requests for help for the full set of 26 ESRA-C
SxQOL issues; and 2) reports of individual SxQOL issues
within the full set, plus 3) to determine whether any ob-
served differences would account for differences in symp-
tom distress.Methods
This analysis is one component of a program of research
founded on the Quality Health Outcomes Model, a frame-
work proposed by Mitchell and colleagues [19] to illus-
trate that patient outcomes are rarely explained only by
specific interventions but also by health care system/pro-
vider factors and patient-specific factors. Patients' verbal
behaviors can be placed in the model (Figure 1) as a
patient-specific factor that may mediate, along with setting
factors such as clinician verbal behaviors, the impact of
the ESRA-C intervention on symptom distress.
Design, sample, intervention
The ESRA-C II trial was a randomized trial conducted
at two comprehensive cancer centers. The study was ap-
proved by both the Dana-Farber/Harvard Cancer Center
and the Fred Hutchinson Cancer Institute Institutional
Review Boards. Participants were patients with various
cancers at a range of stages. The details of the trial were
reported elsewhere [18]. In brief, adult patients who pro-
vided written informed consent to participate and were
about to start a new medical or radiation anti-cancer ther-
apy were randomized to receive usual education about
SxQOL topics or usual education plus tailored self-care
instruction for moderate-to-severe reported SxQOL is-
sues. In both arms, patients reported SxQOL using the
ESRA-C and clinicians received summaries of patient-
reported SxQOL prior to treatment (T1) and again
within 24 hours prior to a face-to-face clinic visit (T2).
Cancer symptomatology was measured primarily with
the Symptom Distress Scale-15 (SDS-15), adapted from
the 13-item, legacy instrument developed by McCorkle
and Young [20] and validated in many subsequent stud-
ies and languages [21]. The SDS-15 offers patients with
cancer the opportunity to report most of the common
symptoms and side effects of therapy in an easy-to-
understand format. Patients in the intervention group
could access the ESRA-C program from home or in
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out the trial to electronically track SxQOL and view
self-care instruction.
The patient instruction in the intervention arm in-
cluded on-screen, tailored coaching on how to better
communicate each troublesome SxQOL issue to the
clinician, and specifically to remind and encourage the
patient to describe the severity, pattern, and alleviating/
aggravating factors related to the issue, and to ask for
assistance in managing the issue. Figure 2 depicts an ex-
emplar of the communication coaching text. These
coaching instructions were delivered immediately before
each on-study clinic visit for the 14.5% (109/752) of the
sample without remote access to the ESRA-C program
and within 24 hours of the visits for those patients with
remote access at home (85.5%).
About six weeks after study enrollment and treatment
initiation (T2), a regularly scheduled clinic visit between
the participant and clinician was audio-recorded. All re-
cordings were cleaned of potential identifiers. Research
team members listened to the recordings using Sound
Forge Audio Studio software version 9 (Sony Creative
Software, Middleton, WI) and coded the following for
each of 26 SxQOL issues (including a field for free text
entry of SxQOL not specifically assessed): a) who initi-
ated; b) whether the issue was discussed and defined as
problematic; and c) which, if any, of the four coachedFigure 2 Exemplar of online coaching regarding self-care and commudescriptions/requests (severity, pattern, alleviation/ag-
gravation and request for help) the patient and/or care-
giver made without clinician prompting. We defined the
SxQOL issue problematic when it was discussed as
current at any degree of severity.
Members of the study team were trained to code re-
cordings and completed eight practice cases with feed-
back to achieve proficiency prior to initiating coding.
The team met to review and discuss coding monthly
over fourteen months. Coders were blinded to group as-
signment unless it was disclosed during the course of
the recorded clinic visit. Cases were assigned for coding
randomly. Twelve percent of cases were randomly se-
lected to be double-coded for reliability; percent agree-
ment was calculated in which every matched code was an
agreement (for example, both coders identify an utterance
as a description of the pattern of a particular symptom),
and every unmatched code was a disagreement (for ex-
ample, one coder identified the patient and another the
family member as the initiator of a particular symptom
discussion). When there were disagreements, the coders
reviewed codes together and determined the final codes
used for analysis.
Analytic methods
Descriptive statistics were used to summarize baseline sam-
ple characteristics and numbers of SxQOL issues identifiednication.
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age of problematic issues initiated by the patient, family or
clinician was calculated. Among problematic SxQOL issues,
two measures were defined for analysis across all patients:
1) the percentage of problematic issues about which the
patient or caregiver verbally reported at least one coached
statement without clinician prompting; and 2) a report
index of how many coached statements were made by the
patient during the visit), regarding problematic SxQOL is-
sues (for example, if a patient reported only severity for fa-
tigue, the measure would be 1/4 = .25).Assessed for eligiEnrollment
Random assignm
Time 1
Allocated to intervention (n=389)
Received allocated intervention (n=374)
Did not receive allocated intervention 
(did not meet inclusion criteria) (n=15)
Alloca
Time 2 
Responder (n=326)
Non-responder (n=48)
Deceased (n=4)
Refused/withdrew from study (n=11)
Too ill (n=18)
Unable to contact (n=15)
Visit recorded (n=256)
Visit not recorded (n=70)
Patient declined to be recorded (n=12)
Clinician declined to be recorded (n=23)
Schedule change, no time to record visit (n=25)
Recorder operation failure (n=6)
Other (n=4)
Follow
Analyzed (n=256)
Analy
Figure 3 Analytic sample of 517 audio recorded clinic visits.The range of both measures was from 0 to 1. The Wil-
coxon rank test was used to compare the measures be-
tween study groups. Covariates previously identified as
influencing symptom distress in the primary outcome
analysis (age, clinical service, working status and base-
line SDS-15 score) were adjusted in multivariable
analysis to improve the precision of estimating the
intervention effect on the two scores. Two-way interac-
tions between study group and other covariates were
tested and none were found significant. In addition, for
each individual SxQOL, the percentage of problematicbility (n=2,234)
Excluded (n=1,455)
Not meeting inclusion criteria (n=576)
Declined to participate (n=879)
ent (n=779)
Time 1
Allocated to control (n=390)
Received allocated control (n=378)
Did not receive allocated control
(did not meet inclusion criteria) (n=12)
tion
Time 2 
Responder (n=352)
Non-responder (n=26)
Deceased (n=2)
Refused/withdrew from study (n=6)
Too ill (n=7)
Unable to contact (n=9)
Declined to answer at Time 2 only (n=2)
Visit recorded (n=261)  
Visit not recorded (n=91)
Patient declined to be recorded (n=23)
Clinician declined to be recorded (n=21)
Schedule change, no time to record visit (n=33)
Recorder operation failure (n=4)
Other (n=10)
-Up
Analyzed (n=261)
sis
Table 1 Baseline patient characteristics for those with an
audio-recorded visit (N = 517)
Study group
Control Treatment
n = 261 n = 256
n (%) n (%)
Age
< 50 56 21.5 96 37.5
≥ 50 205 78.5 160 62.5
Median (range) 59 (22–87) 55 (22–86)
Gender
Male 142 54.4 123 48.0
Female 119 45.6 133 52.0
Clinical Service
Medical Oncology 144 55.2 151 59.0
Radiation Oncology 87 33.3 86 33.6
HSCT 30 11.5 19 7.4
Working Status
Missing 33 12.6 16 6.3
Not Working 72 27.6 81 31.6
Working full/part time 156 59.8 159 62.1
Cancer Type
Bladder 8 3.1 5 2.0
Breast 70 26.8 81 31.6
Colorectal 21 8.0 28 10.9
Gastrointestinal, not colorectal 47 18 47 18.3
Head and Neck 15 5.7 12 4.7
Leukemia/lymphoma/myeloma 41 15.7 30 11.8
Prostate 48 18.4 49 19.1
Other 21 8 16 6.3
Missing 8 3.1 5 1.9
Stage
0 8 3.1 2 0.8
1 44 16.9 39 15.2
2 60 23.0 67 26.2
3 38 14.6 56 21.9
4 73 28.0 65 25.4
N/A 3 1.1 0 0
Missing 35 13.4 27 10.5
SDS-15 (T2) mean (SD) 27.0 (8.12) 26.6 (7.73)
SD, standard deviation.
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groups with a Fisher’s Exact test.
In order to assess whether patient verbal reports medi-
ated the outcome of the primary analysis [18], reduced
symptom distress, we conducted a mediation analysis using
a causal step approach [22]. Specifically, for the analytic
sample (participants with audio recordings), the difference
in SDS-15 from baseline to study end was calculated. Then
three regression analyses were performed: 1) SDS-15 differ-
ence on study group, adjusting for baseline SDS-15 score;
2) patient verbal report measure on study group; and 3)
SDS-15 difference on study group and patient verbal report
measure, adjusting for baseline SDS-15 score. The medi-
ation would be established if all of the following were
observed: significant relationships in regression 1 and 2;
significant relationship of patient verbal report measure
with SDS-15 difference in regression 3; and a smaller coef-
ficient of the study group in regression 3 compared with
regression 1. We tested the mediation effect of each patient
verbal report measure separately. Lastly, the percentage of
problematic SxQOL issues for which clinicians verbalized a
treatment or referral was calculated for each patient and
compared between two study group with the Wilcoxon
rank test. For all tests, a two-sided p-value of 0.05 was con-
sidered statistically significant and 0.1 was considered to
indicate a trend.
Results
Among 752 eligible patients, 517 clinic visits were audio-
recorded and coded for analysis (Figure 3). In one record-
ing, the patient referenced teaching material in the online
intervention, effectively un-blinding the coder to group as-
signment. Sixty-two recordings were double-coded, with a
mean percent agreement of 86.7 (median 88.0; range 61.0-
99.5). Of the recordings available for analysis, 261 were
from the control group patients and 256 from the inter-
vention group. Baseline participant characteristics are
presented by study group in Table 1. Patients with audio-
recordings were younger in the intervention group than in
the control group (p < .0001). Out of 517 patients, 27 (13
control and 14 intervention) did not discuss any problem-
atic SxQOL issue during the clinic visits. There was no
significant difference (p = 0.41) between study groups in
number of problematic SxQOL issues discussed at all
during clinic visits, with a median of 4 issues discussed
by control group patients, and 3 by patients in the inter-
vention condition. Patients initiated general discussion
of an average 56% of problematic SxQOL issues in the
control group and 55% in the intervention group (p =
0.97). Family members initiated 4% of the problematic
SxQOL issues in the control group and 5% in the inter-
vention group (p = 0.35).
The percentage of problematic SxQOL issues which pa-
tients or caregivers reported using any specific coachedstatement during the clinic visit, was significantly higher
(p = 0.002) in the intervention group than that in the
control: a median of 85% of problematic SxQOL were
reported as coached in the intervention group versus
75% in the control (Table 2). After adjusting for covariates,
group remained significantly associated (p = 0.0009);
Table 2 Problematic SxQOL verbally reported with any
coached statement(s) and index of coached statements
per SxQOL (N = 517)
% reported by
patients
Index of coached
statements reported
by patients
Median Mean (SD) Median Mean (SD)
(Q1, Q3) (Q1, Q3)
Control (n = 261) 0.75 0.68 (0.32) 0.25 0.29 (0.18)
(0.50, 1.00) (0.17, 0.40)
Treatment
(n = 256)
0.85 0.77 (0.27) 0.31 0.33 (0.17)
(0.60, 1.00) (0.21, 0.43)
Q1 = lower quartile (25th percentile).
Q3 = upper quartile (75th percentile).
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rate of describing problems with a coached statement
(Table 3).
The report index of coached statements was signifi-
cantly higher (p = 0.01) in the intervention group than
in the control group, with medians of 0.31 and 0.25, re-
spectively (Table 2). In other words, a patient with four
discussed problematic issues in the intervention group
gave one more coached, specific statement than a similar
patient in the control. In the multivariable model adjust-
ing for potential covariates (Table 3), study group was
the only factor significantly associated (p = 0.03) with re-
port index scores. Patients in the intervention group had
an average 0.036 higher report index than those in the
control group.
Figure 4 displays the percentage of participants report-
ing any coached statement for each problematic SxQOL.
The most frequently described issues in both groups were
those related to symptoms versus quality of life domains.
The percentage in the intervention group was significantly
higher for fatigue (p = 0.03), pain (p = 0.02) and physical
function (p = 0.02), and trended higher for bowel (p =
0.08), sensory neuropathy (p = 0.07), and SxQOL issuesTable 3 Multivariable regression analysis of percentage of pr
coached statement, and of index of coached statements (N =
% SxQOL reported by pat
Est. 95% CI
Study Group 0.090 0.033 to 0.15
(Intervention vs. control)
Age −0.0000 −0.0024 to 0.0024
Service
HSCT vs. RadOnc 0.10 −0.0015 to 0.20
MedOnc vs. RadOnc 0.055 −0.0094 to 0.12
Work Status −0.0001 −0.064 to 0.063
(Not working vs. working full/part time)
Baseline SDS15 0.0017 −0.0023 to 0.0056reported by patients in free text entry (p = 0.09). However,
the percentage of specific, coached descriptions of nau-
sea was significantly lower in the intervention group
(p = 0.04).
Of 517 patients with audio data, 445 had SDS-15
scores at baseline and the study endpoint, and thus were
included in the mediation analysis. Significant relation-
ships were confirmed between study groups and SDS-15
difference (p = 0.05) in the first regression, and study
group and patient verbal report measures in the second
regressions (p = 0.0005 for percent of problematic SxQOL
issues reported using any coached statement, and p = 0.01
for the report index). However, when the SDS-15 differ-
ence was regressed on study group and patient verbal re-
port measures in the final pair of analyses, neither of the
two verbal report measures was significant (p = 0.26 for
percent of problematic SxQOL reported using any coa-
ched statement, p = 0.41 for the report index ). The results
suggest that patients' specific verbalization of coached
statements did not mediate the impact of the ESRA-C
intervention on symptom distress. During the recorded
clinic visits, clinicians verbalized treatment or a referral
for a median of 48% of problematic SxQOL issues in the
control group and a median of 50% in the intervention
group (p = 0.15).
Discussion
The patients in the ESRA-C II randomized trial who
received an educational coaching intervention to aid ver-
bal report of problematic SxQOL applied the reporting
framework as coached (severity, pattern, aggravating/
alleviating factors and help request), reporting these spe-
cific details without prompting, significantly more often
than control group patients. When examining individual
SxQOL issues, we found that reports for the majority of
individual SxQOL issues were more frequent in the
intervention group. Even though our study was not pow-
ered to compare individual SxQOL issues, we found thatoblematic SxQOL which patients reported using any
517)
ients Index of coached statements reported by patients
P-value Est. 95% CI P-value
0.002 0.037 0.003 to 0.071 0.03
1.0 −0.0005 −0.0020 0.0009 0.5
0.10 0.1
0.05 0.042 −0.018 to 0.10 0.2
0.09 0.039 0.0006 to 0.077 0.05
1.0 0.0018 −0.036 to 0.040 0.9
0.4 0.0014 −0.0010 to 0.0037 0.3
Figure 4 Percentage of problematic SxQOL issues reported as coached, by study group. For each SxQOL issue, the number of patients'
visits (n control, n intervention) in which the issue was defined as a problem is shown and the percentage of visits in which the patient or
caregiver made unprompted reports of severity, pattern, or alleviating/aggravating factors, or requested help for the SxQOL issue. (*) denotes a
p-value of ≤ .05 for the difference between study groups in reporting percentage.
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cantly more often by the intervention group. Fatigue is
known to be the most common cancer symptom [23],
pain also has a high incidence, and physical functioning
is impacted by both. Interestingly, specifics of problem-
atic nausea were reported significantly less often in the
intervention group. This may reflect that intervention
patients were intent on reporting other SxQOL issues
perceived to be more important or more difficult to
manage, and consequently, nausea was not one of the
priorities.
Findings from our previous randomized trial with
ESRA-C [17] and from Velikova et al. [16] established
the significant and positive effect of a clinician summary
on verbal discussions of SxQOL within a face-to-face
clinic visit, yet neither trial significantly increased patient
verbal self-reports. Instructing the participant to verbally
report the same information reported on the quantitative
SxQOL questionnaires was not included in these earlier
trials. Of all the trials conducted with SxQOL outcomes,
very few have utilized a direct measure of patient-provider
communication [24]. Wilkie and colleagues [25] random-
ized 151 patients with lung cancer and found significantly
more unsolicited reports of pain intensity in audio-recordings of on-treatment clinic visits after an interven-
tion consisting of a coaching videotape plus personal
reinforcement. Street et al. [26] reported that, in 148
patients with cancer randomized to an educational com-
munication coaching intervention, higher baseline pain
and several demographic variables predicted more pain-
specific active participation in the clinic visit conversation.
Taking all of these results together, coaching patients with
cancer to engage in conversations with specialists moni-
toring the treatment course shows promise as an adjunct
to providing clinicians with quantitative information from
SxQOL questionnaires. The use of electronic self-report
and education further enhanced the method. Not only
did it save data entry time but it also provided custom-
ized, immediate patient coaching for the problems of
highest intensity or distress, and a quick-to-view sum-
mary for the clinicians.
Our findings may be limited by the fact that the audio-
recording was made at only one visit, a cross-section of
the entire cancer treatment experience. Clinicians may
have taken actions relevant to SxQOL issues after the visit
or even in the next weekly visit that impacted the symp-
tom distress outcome. Also, while we observed a signifi-
cantly younger mean age of patients in the intervention
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based instruction than the older control group, our
analyses suggest that younger age was not a significant
covariate influencing the outcomes. Our sample was pre-
dominately a group of educated health care recipients be-
ing cared for in two comprehensive cancer centers; [17]
thus these findings only can be generalized beyond such a
sample and setting with caution.
These analyses clearly suggest that communication
from patients to clinicians with regard to SxQOL may
be improved with our intervention, yet many issues
remain to be addressed: 1) whether the effect of the inter-
vention was related to how often patients utilized the self-
monitoring and teaching components; and 2) whether
patients in the intervention group adhered more often to
SxQOL management recommendations made by clini-
cians. Future analyses are clearly warranted to address
these issues and understand more fully the effect of such
intervention on patient-reported outcomes.
Conclusions
Electronic education and coaching provided to patients
with a variety of cancers of all stages resulted in signifi-
cantly more specific verbal reports of SxQOL concerns
made to treating clinicians in face to face visits. While
there is evidence that the coached approach to describing
SxQOL was adopted, the specific concerns verbalized by
patients in one visit did not mediate the overall study out-
come of symptom distress. The rate at which clinicians
responded verbally with actions to address the concerns
was not significantly different between groups. Other
unknown or unanalyzed variables may explain why
patients in the intervention group of the ESRA-C II trial
reported lower symptom distress over the course of can-
cer treatment.
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